At the time of writing, Black Diamond Therapeutics Inc [BDTX] stock is trading at $2.75, up 4.17%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BDTX shares have gain 5.77% over the last week, with a monthly amount drifted -0.36%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Black Diamond Therapeutics Inc [NASDAQ: BDTX] stock has seen the most recent analyst activity on December 03, 2025, when Guggenheim downgraded its rating to a Neutral. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $8 on September 04, 2025. Raymond James started tracking with an Outperform rating for this stock on July 31, 2024, and assigned it a price target of $20. In a note dated July 14, 2023, Piper Sandler initiated an Overweight rating.
For the past year, the stock price of Black Diamond Therapeutics Inc fluctuated between $1.20 and $4.94. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Black Diamond Therapeutics Inc [NASDAQ: BDTX] shares were valued at $2.75 at the most recent close of the market. An investor can expect a potential return of 190.91% based on the average BDTX price forecast.
Analyzing the BDTX fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.31%, and Net Profit Margin reading is 0.31%. To continue investigating profitability, this company’s Return on Assets is posted at 0.14, Equity is 0.18 and Total Capital is 0.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Black Diamond Therapeutics Inc [NASDAQ:BDTX] has a current ratio of 8.94. Further, the Quick Ratio stands at 8.94, while the Cash Ratio is 1.99. Considering the valuation of this stock, the price to sales ratio is 2.24, the price to book ratio is 1.24 and price to earnings (TTM) ratio is 7.58.
Transactions by insiders
Recent insider trading involved BIOTECH GROWTH N V, 10% Owner, that happened on Mar 19 ’25 when 5.78 million shares were sold.
